Utility of Green Chemistry for Sustainable Fluorescence Derivatization Approach for Spectrofluorimetric Quantification of Pemetrexed as Antineoplastic Drug in Pharmaceutical Formulation and Spiked Human Plasma.

Pemetrexed is a chemotherapeutic medicine, under the trade name Alimta. Malignant pleural mesothelioma patients. Its application in lung cancer has been studied. Here in, a second spectrofluorimetric method was advanced for quantifying of Pemetrexed in pharmaceutical formulation and spiked human plasma. That method depends on fluorescence derivatization of Pemetrexed with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) at 75 °C in a (pH 9) of borate buffer to produce a fluorescent derivative which can be detected at 520 nm afterwards excitation at 460 nm. The method has been validated using ICH criteria, and it demonstrated linearity in a range of 2-120 ngmL-1. The proposed method was applied precisely and accurately for quantifying Pemetrexed within pharmaceutical formulation and spiking human plasma without any interferences. Moreover, the method's sustainability was evaluated and compared to the published method using two greenness assessment tools termed analytical eco-scale and Analytical GREENness (AGREE). That findings suggest that the method is more sustainable than the published method.

Simultaneous Determination of Ceftazidime in Three Different Pharmaceutical Preparations Combined with Either Tazobactam, Tobramycin or Sulbactam by HPTLC-Spectrodensitometric Method.

A new, simple hight performance thin layer chromatography (HPTLC)-Spectrodensitometric strategy was created and approved for the synchronous estimation of four antibacterial specialists: ceftazidime (CEF), tazobactam (TAZ), tobramycin (TOB) and sulbactam (SUL). The four compounds were separated on TLC aluminum plates covered with silica gel 60 F254, using chloroform-acetonitrile-methanol-ammonia (4:1:0.5:0.15, v/v/v/v) as a mobile phase at 254 nm. Linear correlation was obeyed over the concentration ranges of 12.0-72.0, 2.0-12.0, 3.0-18.0 and 10.0-50.0 µg mL-1 for CEF, TAZ, TOB and SUL, respectively. The proposed approach is efficient, repeatable and convenient as a flexible method for the quality control of diverse combinations of these pharmaceuticals in various pharmaceutical preparations, with high percent recoveries that are highly consistent with labeled data. When the findings of the proposed technique were compared to those of the comparison methods, there were no critical contrasts in terms of precision and accuracy.

Green micellar spectrofluorimetric determination of α-mangostin found in herbal products as antioxidant and other biological activities beneficial to human health.

Pharmaceutical product quality control (QC) needs quick, sensitive and economical procedures to deliver high throughput at low cost, which is the key factor considered by such economic facilities. To lessen the risky effects of research laboratories, researchers must take into account the ecological impacts. α-Mangostin (MAG) exhibit anti-inflammatory, antioxidant, anticancer, anti-allergic, antibacterial, antifungal, antiviral and antimalarial activities. Based on the spectrofluorimetric approach, a novel straightforward, sensitive and environmentally friendly method for MAG determination was developed and validated. Many variables were investigated to improve MAG native fluorescence, including solvent type, buffers, pH and additional surfactants. The best MAG fluorescence sensitivity was found in Britton-Robinson buffer (pH 4) at 450 nm after irradiation at 350 nm in the concentration range of 5-50 ng ml-1 . The technique was successfully used to determine the presence of MAG in both its approved dose forms and in samples of spiked human plasma, as per FDA standards for validation. According to their evaluation on two recent greenness criteria (GAPI [Green Analytical Procedure Index] and AGREE [Analytical GREEnness]), the suggested approach has been shown to be environmentally beneficial because it normally uses biodegradable chemicals in solvent-free aqueous phases.

Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma.

The combination of olanzapine and samidorphan has just been authorised for the treatment of schizophrenia. The current study created a very accurate, sensitive and selective spectroscopic technique based on the first derivative of synchronous fluorescence for determining olanzapine and samidorphan in their pharmaceutical prescriptions without prior separation. For the quantitative analysis of samidorphan and olanzapine, the adopted approach is focused on measuring the synchronised fluorescence intensity of the examined medicines at fixed wavelength range (Δλ) = 50 nm and the first derivative's peak magnitudes were observed at 300 and 350 nm, respectively. The effects of various factors on the synchronised fluorescence intensity of the referenced medications were researched and adjusted. Both medications' calibrating charts were shown to be linear throughout a range of concentrations of 0.1-1.1 µg mL-1. LOD for SAM and OLA were 0.02 and 0.01, respectively. In addition, LOQ was determined for SAM and OLA as follow, 0.07 and 0.06, respectively. The devised approach was effectively used to the quantitative measurement of the two medicines in Lybalvi® tablets with various samidorphan and olanzapine ratios, in addition to spiked human plasma. A variance ratio F-test and student t-test were needed to be able to compare the results to another published analytical technique and found no significant differences.

Utilization of a complex arrangement approach for spectroscopic examination with Eosin Y of various cephalosporins in their pure or pharmaceutical dosage forms, and in human plasma.

Approved, basic, effective and successful spectroscopic strategies (spectrophotometric and spectrofluorimetric) were created to measure seven cephalosporins: cefpiramide (I), cefuroxime (II), cefoxitin (III), ceftazidime (IV), cefpirome (V), ceftobiprole (VI), and ceftriaxone (VII). These strategies used a two-fold complex arrangement response for the drug amino groups with Eosin Y (EY). The examined drugs were determined spectrophotometrically at 542-550 nm in acetic acid derivative buffer. The examined drugs were determined spectrofluorimetrically by measuring their quenching effect on EY local fluorescence at 545 nm after excitation at 305 nm. The absorbance-intensity plots were rectilinear over the ranges 20-100, 10-130, 20-220, 30-230, 10-210, 20-180 and 10-130 µg ml-1 for I, II, III, IV, V, VI, and VII samples, respectively. The fluorescence-intensity plots were rectilinear over the ranges 0.5-1.5, 0.1-0.9, 0.3-1.5, 0.5-2.5, 0.1-0.9, 0.5-2.5 and 0.1-1.0 µg ml-1 for I, II, III, IV, V, VI, and VII samples, respectively. The recommended materials were certified as adhering to International Council for Harmonisation (ICH) guidelines and were used to examine the tested drugs in different dosage forms and in human plasma tests. The approved materials matched the reference materials.